Lipid Library for LNPs and Ready-to-Use Delivery Reagents
Non-viral delivery of nucleic acids for RNA & DNA based therapeutics offer a powerful alternative to viral vector delivery. Complimentary to our range of upstream solutions to produce viral vectors for gene and cell therapies, our non-viral delivery solutions help meet the challenges of in vitro, ex vivo and in vivo gene delivery:
- Our ready-to-use solutions simplify genetic material delivery, ensuring cost-efficiency, speed, and versatility
- Our innovative library of proprietary cationic lipids unlock new LNP-based therapies with extrahepatic targeting
Explore Our Non-Viral Solutions
Whether for research or therapeutic applications, Sartorius solutions deliver the flexibility, reliability and efficiency needed to accompany you from initial research to process development and manufacturing.
Ready-to-use Cationic Polymer for In Vivo Nucleic Acid Delivery
The gold standard for in vivo delivery of DNA, siRNA/miRNA, shRNA & other oligos:
- Proven & Successful: 650+ peer-reviewed articles, with several ongoing Human clinical trials, up to Phase 3
- Cost-Efficient: Ready-to-use reagent with no need for equipment or consumables
- GMP-compliant: Available in research and GMP grades; with DMF submitted to FDA
Ready-to-Use Lipid-based Nanoparticles for in vivo mRNA Transfection
A highly efficient, user-friendly alternative to LNPs for in vivo delivery:
- Cost-Efficient: Ready-to-use with no need for equipment or consumables
- Reliability: Ensures 100% mRNA encapsulation for high in vivo delivery efficiency
- Versatile: For mRNA, circRNA, saRNA, gRNA via any administration route
- Safe: Keeps animals healthy with low pro-inflammatory response
Democratizing Gene-Modified Cell Therapy, Delivering Excellence
Ready-to-use Lipid-based Nanoparticles for Ex Vivo Transfection of Immune and Stem Cells
- Cost-Efficiency: Ready-to-use reagent, with no specific equipment nor consumables required
- High Performance: Excels in transient expression & stable modification using gene editing tools
- High Cell Viability: Preserves cell viability, growth and function
- Scalability: Suitable for well-plate screenings to bioreactor production
- Flexibility: Accommodates diverse nucleic acid payloads across various cell types
Innovative Cationic Lipids for Improved LNP Targeted Formulation
A novel range of cationic lipids for LNP formulation:
- Efficient: Modulates LNP properties for optimal efficacy and biodistribution
- Secure: Unique lipid structure protected by independent IP
- Time-Saving: Extensive data with openly shared formulations, backed by dedicated support teams and documentation
- Flexible: Library format to screen for ideal lipid per therapeutic application
Featured Assets
Related Webinars
FAQs - Non-Viral Delivery Solutions
LipidBrick® LNPs or in vivo-jetRNA®+ can be used in vitro for mRNA validation. However, in vivo-jetPEI® is not suitable for in vitro delivery, and we recommend using jetPEI®. Refer to product ‘Instructions for Use’ for starting conditions.
The route of administration largely affects biodistribution. LipidBrick® Library enables customizable LNP formulation for specific biodistribution. Our cationic solutions tend to target lung and spleen rather than liver. Please contact our technical support team for precise advice polyplus-support@sartorius.com .
The use of commercial mRNA is recommended or purified home-made mRNA with phenol-chloroform and isopropanol, avoiding salt-based methods. Ensure OD260/280 > 2. Chemically 5’ capped and modified mRNA can enhance gene expression.
Sartorius ready-to-use solutions come with a 2-step protocol, ready in 15-20 mins. For LipidBrick® lipids, we recommend either microfluidics, T-junction or ethanol injection. Hand-mixing can also be used, though this may reduce homogeneity of your lipid nanoparticles.
The LipidBrick® Library features proprietary cationic lipids with an imidazolium polar head, designed to offer enhanced safety compared to traditional cationic lipids. We exclusively supply these specific lipids. Additionally, we provide pre-formulated, ready-to-use lipid-based nanoparticle solutions, which serve as alternative delivery methods to lipid nanoparticles (LNPs) for nucleic acid delivery, such as in vivo-jetRNA®+ and LipidBrick® Cell Ready.
